Searchable Patents Journal

Search details
          Search details help

   Results per page

Currently viewing: Intellectual Property Office - Patents Journal : SPCs
From 2020 July 08th - 6842 to 2020 July 08th - 6842
Refine: 

  • Help on this tab
    • Page
    • Previous
    • 1
    • Next
Publication
Date
SPC No.SPC
Category
Details
Rows may repeat to show multiple inventors or applicants depending on "Sort By"
08 July 2020
(Journal 6842)
SPC/GB14/069GrantedApplicant: Otsuka Pharmaceutical Co., Ltd
9 Kandatsukasa-cho 2-chome, Chiyoda-ku, Tokyo, 101-8535, Japan

Product: Delamanid optionally in the form of a pharmaceutically acceptable salt

Product Type: Medicinal
Authorised: UK EU/1/13/875/001-004 30 April 2014

Authorised Extension:

Patent No: EP1555267
Title: 2,3-DIHYDRO-6-NITROIMIDAZO[2, 1-b]OXAZOLES

SPC No: SPC/GB14/069
Date Granted: 12 June 2020
Maximum Period Expires On: 9 October 2028
08 July 2020
(Journal 6842)
SPC/GB15/017GrantedApplicant: Nissan Chemical Industries, Ltd.
7-1, Kanda Nishiki-cho 3-chome, Chiyoda-ku, Tokyo 101-0054, Japan

Product: Fluralaner or a salt thereof

Product Type: Medicinal
Authorised: UK EU/2/13/158/001-015 13 February 2014

Authorised Extension:

Patent No: EP1731512
Title: Isoxazoline-substituted benzamide compound and noxious organism control agent

SPC No: SPC/GB15/017
Date Granted: 12 June 2020
Maximum Period Expires On: 12 February 2029
08 July 2020
(Journal 6842)
SPC/GB15/023GrantedApplicant: PTC Therepeutics, Inc.
100 Corporate Court, Middlesex Business Centre, South Plainfield, NJ 07080., USA

Product: 3-[5-(2-Fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid (i.e. Ataluren)

Product Type: Medicinal
Authorised: UK EU/1/13/902/001 5 August 2014

Authorised Extension:

Patent No: EP1618098
Title: 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease

SPC No: SPC/GB15/023
Date Granted: 12 June 2020
Maximum Period Expires On: 8 April 2029
08 July 2020
(Journal 6842)
SPC/GB18/019Entered Into ForceApplicant: Kyowa Kirin Co., Ltd.
1-9-2 Otemachi, Tokyo 100-0004, Japan

Product: Benralizumab, an afucosylated antibody that binds to interleukin-5 receptor alpha

Product Type: Medicinal
Authorised: UK EU/1/17/1252 10 January 2018

Authorised Extension:

Patent No: EP2270149
Title: Method for controlling the activity of immunologically functional molecule

SPC No: SPC/GB18/019
Date entered into force: 10 June 2020
Effective Period Expires On: 6 April 2025
08 July 2020
(Journal 6842)
SPC/GB20/023LodgedApplicant: Novartis AG
Lichstrasse 35, 4056 Basel, Switzerland

Product: glycopyrronium or a salt thereof, especially the bromide salt, and indacaterol maleate, in combination

Product Type: Medicinal
Authorised: UK EU/1/13/862 23 September 2013

Authorised Extension:

Patent No: EP2228064
Title: Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist

SPC No: SPC/GB20/023
Date Lodged: 9 June 2020
08 July 2020
(Journal 6842)
SPC/GB20/024LodgedApplicant: Gilead Sciences, Inc
333 Lakeside Drive, Foster City, California 94404, USA

Product: Cobicistat or a pharmaceutically acceptable salt or solvate thereof, darunavir or a pharmaceutically acceptable salt or solvate thereof, in particular darunavir ethanolate, and emtricitabine or a pharmaceutically acceptable salt or solvate thereof.

Product Type: Medicinal
Authorised: UK EU/1/17/1225 25 September 2017

Authorised Extension:

Patent No: EP3150586
Title: Modulators of pharmacokinetic properties of therapeutics

SPC No: SPC/GB20/024
Date Lodged: 9 June 2020
08 July 2020
(Journal 6842)
SPC/GB20/025LodgedApplicant: Anacor Pharmaceuticals, Inc.
235 East 42nd Street, New York,, NY, 10017, USA

Product: crisaborole, optionally in the form of a pharmaceutically acceptable salt

Product Type: Medicinal
Authorised: UK EU/1/19/1421 1 April 2020

Authorised Extension:

Patent No: EP2343304
Title: Biocidal boronophthalide compounds

SPC No: SPC/GB20/025
Date Lodged: 1 June 2020
  • Page 1 of 1 (7 hits)
  • Page
  • Previous
  • 1
  • Next

Tell us about a problem